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Abstract
Transmissible spongiform encephalopathies (TSEs) are caused by the prion, which consists
essentially of PrPSc, an aggregated, conformationally modified form of the cellular prion pro-
tein (PrPC). Although TSEs can be experimentally transmitted by intracerebral inoculation,
most instances of infection in the field occur through extracerebral routes. The epidemics of
kuru and variant Creutzfeldt-Jakob disease were caused by dietary exposure to prions, and
parenteral administration of prion-contaminated hormones has caused hundreds of iatro-
genic TSEs. In all these instances, the development of postexposure prophylaxis relies on
understanding of how prions propagate from the site of entry to the brain. While much evi-
dence points to lymphoreticular invasion followed by retrograde transfer through peripheral
nerves, prions are present in the blood and may conceivably cross the blood-brain barrier
directly. Here we have addressed the role of the blood-brain barrier (BBB) in prion disease
propagation using Pdgfbret/ret mice which possess a highly permeable BBB. We found that
Pdgfbret/ret mice have a similar prion disease incubation time as their littermate controls
regardless of the route of prion transmission. These surprising results indicate that BBB per-
meability is irrelevant to the initiation of prion disease, even when prions are administered
parenterally.
Author summary
Prion diseases or transmissible spongiform encephalopathies (TSEs) are incurable brain
diseases caused by conformational changes in the endogenous prion protein. Prions can
be transmitted through contaminated food, surgical instruments and blood. Transmission
of prions has caused the kuru epidemic in humans and bovine spongiform encephalopa-
thy in cattle, which in turn caused variant Creutzfeldt-Jakob disease (CJD) in humans.
Furthermore, injection of prion-contaminated hormones has caused hundreds of TSE
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cases. In order to develop drugs to prevent the spread of prions into the brain after expo-
sure via food or medical procedures, it is necessary to gain an understanding of how pri-
ons propagate from the site of entry to the brain. Prions were shown to reach the spinal
cord by traveling along peripheral nerves. However, prions are also found in blood.
Although normal brain vessels act as a barrier between the blood and brain, some studies
suggested that prions in blood may enter the brain via blood vessels. Here we have tested
the latter hypothesis using mice with increased brain blood vessel permeability. We found
that these mice are similar to wild-type mice in their susceptibility to prion disease and
incubation times after peripheral inoculation. These results suggest that passage of prions
through the blood-brain barrier may not be relevant to the development of disease, and
imply that any effective post-exposure treatment should rather aim at other rate-limiting
steps of prion propagation.
Introduction
Transmissible spongiform encephalopathies (TSEs) are progressive, invariably lethal neurode-
generative diseases which include Creutzfeldt–Jakob disease, kuru, fatal familial insomnia and
Gerstmann–Stra¨ussler–Scheinker syndrome in humans, scrapie in sheep, and bovine spongi-
form encephalopathy (BSE) in cattle [1]. The infectious agent, termed prion, consists primarily
of PrPSc, a conformationally modified form of PrPC, a protein encoded by the gene PRNP [2].
Conversion of PrPC into PrPSc leads to accumulation of insoluble, partially protease-resistant
prion protein deposits in the brain parenchyma around neurons and neuronal loss which is
accompanied by gliosis and spongiform changes. Deletion of PrPC renders mice resistant to
prion infections, indicating that its conversion into PrPC is necessary for the development of
disease [1].
Although there have been instances of patients intracerebrally infected by prion-contami-
nated medical equipment or by dura mater grafts of cadaveric origin [3], transmission of prion
infections occurs more frequently through peripheral routes. The oral route of transmission
has caused epidemics of kuru and variant CJD in humans, as well as BSE in cows [3]. Likewise,
the parenteral route of prion transmission is highly effective in laboratory mice and hamsters.
But how do prions reach the central nervous system (CNS) upon entering the body from
peripheral sites? After extraneural inoculation, prions accumulate and replicate in lymphoid
tissues [4]. Follicular dendritic cells (FDC) and their precursors may constitute the first site of
prion amplification [1]. Several studies indicate that prions travel to the CNS along peripheral
sympathetic nerves, and the distance between FDC and sympathetic nerve endings specifies
the speed of neuroinvasion [5, 6].
However, none of these findings exclude the possibility that prions, in addition to following
the lymph invasive route, may directly colonize the CNS through hematogenic spread followed
by direct crossing of the brain vasculature. Prions are present in the blood of hamsters, mice
and humans, and it was recently shown that both, PrPc and PrPSc, can cross the blood-brain
barrier (BBB) [7–9]. Whether this contributes to the initial spread of the disease into the CNS
is largely unknown.
Here we have addressed the role of the BBB in prion pathogenesis using a genetically modi-
fied mouse strain (Pdgfbret/ret) which possesses a highly-permeable BBB as the result of the
expression of a platelet-derived growth factor B (PDGF-B) lacking the PDGF-B retention
motif [10, 11]. We show that Pdgfbret/ret mice succumb to prion disease similarly to their
littermate controls regardless of the route of prion transmission. In addition, there are no
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differences in histopathological characteristics of the disease nor in the resistance to the prote-
ase K of PrPSc in the brains of terminally sick Pdgfbret/ret mice compared to the controls. Our
study indicates that although PrPSc can cross the BBB [7, 8], this route of entry into the CNS is
negligible as regards the initiation of the disease when prions are administered intravenously,
and highlights the importance of peripheral replication in prion disease pathogenesis in the
case of blood-borne transmission.
Material and methods
Animals
B6.129-Pdgfb<tm3Cbet> [12] heterozygous mice (Pdgfbwt/ret) in the C57BL/6J genetic back-
ground were crossed to obtain Pdgfbwt/wt, Pdgfbwt/ret and Pdgfbret/ret littermates that were used
for prion infection studies. Pdgfbret/ret animals possess an open BBB [10]. The BBB defect
occurs at the level of endothelial transcytosis and tracers with a wide range in the molecular
weight (1 kDa– 200 kDa) or different chemical composition enter the brain parenchyma in
Pdgfbret/ret animals.
Ethics statement
Animal care and experimental protocols were in accordance with the “Swiss Ethical Principles
and Guidelines for Experiments on Animals”, and approved by the Veterinary office of the
Canton of Zurich (permits ZH130/2008, ZH14/2012, ZH90/2013 and ZH196/2014).
Blood brain barrier analysis
Pdgfbwt/ret and Pdgfbret/ret mice received 2.5mg/20g 70 kDa-dextran conjugated to Texas Red
(Invitrogen, Cat # D1864) via the tail vein. The tracer was allowed to circulate for 5 hours.
Mouse brain tissue was prepared for whole-brain clearing according to published protocols
[13, 14]. Mice were deeply anaesthetized and transcardially perfused with ice cold PBS fol-
lowed by a fixative mixture of 4% acrylamide, 1% paraformaldehyde, 0.05% Bis, 0.25% VA-044
in PBS. Mouse brains were removed and post-fixed in the same fixative for 24 hours at 4 ˚C.
The brains were de-gassed, exposed to gaseous nitrogen, and polymerized for 2.5 hours at 37
˚C. Brains were extracted from the hydrogel and placed in 8% sodium dodecyl sulfate (SDS),
200 mM boric acid, pH 8.5 (clearing solution). Brains underwent clearing by electrophoresis
(4–8 hours). Cleared brains were then washed in PBS. The refractive index was equilibrated
with refractive-index matching solution prepared according to published protocols [14].
Brains were imaged using a custom mesoscale selective plane illumination microscope (mesos-
pim.org) that will be described in detail elsewhere. Images were processed using Image J and
Imaris (Bitplane) software.
Prion inoculation
Mice were infected with the Rocky Mountain Laboratory (RML) scrapie strain (passage 6,
RML6). Three different inoculation routes were used: intracerebral, intravenous and intraperi-
toneal. For inoculations, we used 30 μl of RML6 brain homogenate prepared in a solution of
0.32 M sucrose containing 5% BSA. Control groups of mice received intracerebrally 30 μl of
non-infectious brain homogenate (NBH, 10% w/v) prepared from healthy CD-1 mice. Clinical
assessment and scoring of mice based on the presence of neurological signs (including ataxia,
kyphosis, priapism, leg paresis, lack of grooming) was performed as previously described [15].
Mice were euthanized on the day of onset of clinical signs of scrapie according to the approved
protocols.
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One group of mice was inoculated intracerebrally with 30 μl of RML6 brain homogenate
containing 1.5 log LD50 of infectious agent. Two groups of mice received RML6 intravenously
100 μl of RML6 brain homogenate containing 6 log LD50 and 100 μl of RML6 brain homoge-
nate containing 3 log LD50 of infectious agent. One group of mice received 30 μl of RML6
brain homogenate containing 4.5 log LD50 intraperitoneally. Prism software (www.graphpad.
com) was used to perform statistical analysis. The log-rank test was used to compare the sur-
vival curves between Pdgfbwt/wt, Pdgfbret/wt and Pdgfbret/ret littermates.
Western blot
Brains were homogenized in 0.32 M sucrose in PBS. Total protein concentration was deter-
mined using the bicinchoninic acid assay (Pierce) according to manufacturer’s instructions.
Samples were adjusted to 1 μg/μl and digested with proteinase K (PK) (20 μg/μl) in PBS, 0.5%
SDS and 0.5% NP-40 for 30 minutes at 37 ˚C. Proteinase K reaction was stopped by adding
loading buffer (Invitrogen) followed by boiling samples for 5 minutes at 95 ˚C. PK-treated and
untreated samples were separated on a 12% Bis-Tris polyacrylamide gel (NuPAGE, Invitrogen)
and blotted onto a nitrocellulose membrane. Anti-PrP antibody (POM1, 200 ng ml−1) [16]
was used as a primary antibody which was detected using rabbit anti-mouse IgG1 conjugated
to horseradish peroxidase (HRP). Western blots were developed using Luminata Crescendo
Western HRP substrate (Millipore) and visualized using the FUJI-FILM LAS-3000 system.
The glycoform profiles of PrPSc after PK treatment were quantified using the Quantify One
software (BioRad). The relative intensity of each PrPSc glycoform (i.e. di-, mono-, ungylcosy-
lated) was measured which was expressed then as a percentage of the total signal. Statistical
analysis (two-way ANOVA) was performed using the Prism software (www.Graphpad.com).
Histochemistry and immunohistochemistry
Formalin-fixed tissues were treated with concentrated formic acid for 60 minutes at room tem-
perature to inactivate prion infectivity. Tissue was embedded in paraffin and cut into 2 μm sec-
tions. After deparaffinization through graded alcohols sections were stained with hematoxylin/
eosin. Antibody SAF-84 (A03208, 1:200, SPI-Bio, Waterloo, Australia) was used to detect par-
tially protease-resistant prion protein deposition on a NEXES immunohistochemistry robot
(Ventana Instruments, Basel Switzerland) using an IVIEW DAB Detection Kit (Ventana),
after incubation with protease 1 (Ventana). Microglia was detected using anti-Iba 1 antibody
(WAKO). Sections were deparaffinized through graded alcohols and heat-induced antigen
retrieval was performed in citrate buffer (0.01 M; pH 6). Sections were incubated with anti-
Iba1 Ab (1:2500). Stainings were visualized using DAB (Sigma-Aldrich) and H2O2 (Sigma-
Aldrich), after incubation with a biotinylated secondary antibody (Vector Laboratories) fol-
lowed by the ABC complex solution (Vector laboratories). Sections were counterstained with
Hematoxylin. Images of HE and DAB stained sections were acquired using a NanoZoomer
scanner (Hamamatsu Photonics) and NDPview digital pathology software (Hamamatsu
Photonics).
Quantification of microglia and vacuoles
The quantification of Iba1 positive cells was performed after DAB immunohistochemistry
(n = 4 fields/mouse, n = 3–6 mice/group) using Qupath software (manual quantification func-
tion) [17]. Data were presented as number of Iba1 positive cells/mm2. Quantification of vacu-
oles was performed on HE images ((n = 8 fields/mouse, n = 3–5 mice/group). The algorithm
to count vacuoles was developed in MATLAB R2016B using the Image Processing toolbox.
Image segmentation was performed using Otsu’s thresholding method (T = 0.7). Only round
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vacuoles with an area in the range of [200 pixels, 2000 pixels] and with a shape values> 0.9
(where shape was calculated as shape = (4�π�Area)/(Perimeter^2)) were quantified. The code
is available at: https://github.com/AndraCh/Vacuoles_segmentation. Statistical analysis (one-
way ANOVA) was performed using the Prism software (www.Graphpad.com).
Determination of PK-resistant PrPSc levels by fluorescence-resonance
energy transfer (FRET)
PK-resistant PrPSc was quantified in brain tissue homogenate by FRET using monoclonal anti-
bodies POM1 and POM19 [16]. Protein concentration of samples were determined with a
bicinchoninic acid assay performed according to the manufacturer’s instructions (Thermo
Fisher Scientific). A total amount of 10 μg protein per well was diluted to the correct volume
in PBS. To determine PK-resistant PrPSc levels, samples were PK digested using 50 μg/ml PK
(Roche) at 37˚C for 30 min under constant agitation. Digestion was stopped by adding PMSF
to a final concentration of 2.24 mM and samples were incubated for 10 min at room tempera-
ture (RT). Denaturation of remaining PrPSc in samples was achieved by the addition of NaOH
to a final concentration of 56 mM and samples were incubated for 10 min at RT under con-
stant agitation. To neutralize the samples, NaH2PO4 was added to a final concentration of 66
mM and incubated for 10 min at RT. Samples were pipetted in triplicates to a 384-well Opti-
Plate (Perkin Elmer). For FRET assay we used two in-house produced monoclonal antibodies
recognizing different epitopes of PrP (POM19 and POM1) [16]. POM19 was coupled to Euro-
pium (EU, FRET donor) and POM1 was coupled to allophycocyanin (APC, FRET acceptor).
The antibody pair was diluted in 1X Lance buffer (Perkin Elmer) to a final concentration of
EU-POM19 of 2.5 nM and APC-POM1 of 5 nM. After adding the antibody pair to samples,
the plate was centrifuged at 2000 g for 1 minute and incubated overnight at 4˚C. The following
day, FRET was measured using a multilabel plate reader (EnVision, Perkin Elmer). The excita-
tion wavelength was 337 nm and emission wavelength for EU was 615 nm and for APC 665
nm. Following measurement, the net-FRET signal was used in accordance with formula pub-
lished in [18]. For subsequent analysis, the triplicates were averaged and the signal for non-
infectious brain homogenate was subtracted to remove the background. PrPSc levels are pre-
sented as a ratio of PrPSc in each individual animal to the average of wild-type littermates. Sta-
tistical analysis (one-way ANOVA) was performed using the Prism software (www.Graphpad.
com).
Results and discussion
In order to detect any possible role of the BBB in prion pathogenesis we used Pdgfbret/ret
mice which express a hypomorphic variant of PDGFB [10]. The cerebrovascular tree in these
animals is highly permeable to blood-borne macromolecules, as has been demonstrated in sev-
eral studies using many orthogonal experimental approaches including immunohistochemis-
try, spectrophotometry, MRI [10, 11, 19]. Surprisingly, these mice are viable and enjoy an
almost-normal life span despite their deeply dysfunctional BBB. These findings made it possi-
ble to perform prion infection experiments and study the development of disease over many
months.
Certain areas of the brain are differentially susceptible to neurodegeneration induced by
different prion strains [20]. It is conceivable that the BBB defect of Pdgfbret/ret mice may not
coincide with the areas of selective vulnerability to prions. Therefore, we investigated the
regional characteristics of BBB permeability in Pdgfbret/ret mice using electrophoretic clearing
based on the CLARITY method [13] in custom designed clearing chambers. After receiving an
intravenous injection of 70 kDa dextran conjugated to TexasRed, mice were perfused, brains
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were cleared and then imaged using a mesoscale selective-plane illumination microscope. The
entire brain of Pdgfbret/ret animals showed passage of 70 kDa-dextran Texas Red into the brain
parenchyma (S1B Fig and S1 Movie). The strongest leakage of dextran was detected in the cor-
tex compared to other brain regions, which is in agreement with previously published data
[19]. In control animals (Pdgfbwt/ret), no fluorescent signal can be detected in the brain paren-
chyma (S1A Fig). Thus, these data further demonstrate an enhanced permeability of the BBB
in the entire brain of Pdgfbret/ret mice.
To test whether Pdgfbret/ret and control mice (Pdgfbwt/wt, Pdgfbwt/ret) are competent for
prion replication and succumb into prion disease similarly, mice were inoculated intracere-
brally with RML6. There was no difference in disease incubation between Pdgfbret/ret and con-
trol mice (Pdgfbwt/wt, Pdgfbwt/ret) when infected intracerebrally (Fig 1A).
Inoculation of brain homogenate can induce autoimmune encephalitis, and it is not known
whether such pathology may be exacerbated by a leaky BBB. Therefore, Pdgfbret/ret and control
mice (Pdgfbwt/wt, Pdgfbwt/ret) were inoculated with non-infectious brain homogenate prepared
from CD-1 strain as a control. None of these mice developed clinical signs of disease. They
were sacrificed 350 days post-inoculation and showed no signs of encephalitis or prion pathol-
ogy (Figs 2 and 3 and S2 and S5 Figs).
Fig 1. Increased BBB permeability does not alter prion disease incubation. (A-D) Kaplan-Meier survival curves of Pdgfbwt/wt,
Pdgfbwt/ret, Pdgfbret/ret animals inoculated with RML6 intracerebrally (A) (1.5 log LD50 Pdgfbwt/wt n = 6, 205.5 dpi; Pdgfbwt/ret
n = 7, 222 dpi; Pdgfbret/ret n = 6, 214 dpi, P = 0.22), intraperitoneally (B) (4.5 log LD50 Pdgfbwt/wt n = 7, 225 dpi; Pdgfbwt/ret n = 7,
233 dpi; Pdgfbret/ret n = 7, 232 dpi, P = 0.41) or intravenously (C, D) (3 log LD50 (C) Pdgfbwt/wt n = 6, 248.5 dpi; Pdgfbwt/ret n = 6,
237.5 dpi; Pdgfbret/ret n = 6, 237.5 dpi, P = 0.86 and 6 log LD50 (D) Pdgfbwt/wt n = 6, 223.5 dpi; Pdgfbwt/ret n = 6, 218.5 dpi;
Pdgfbret/ret n = 6, 214 dpi, P = 0.37).
https://doi.org/10.1371/journal.ppat.1007424.g001
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Fig 2. Prion histopathology and vacuolation after RML6 inoculation in control and BBB-compromised mice. (A)
Hematoxylin/eosin stained sections from the cerebella of prion-inoculated (RML6) terminally sick (or control, normal
brain homogenate (NBH) inoculated mice) Pdgfbwt/wt, Pdgfbwt/ret, Pdgfbret/ret animals. i.c.–intracerebral, i.p.–
intraperitoneal, i.v.–intravenous. Quantification of number of vacuoles (B) and area in pixels covered by vacuoles (C)
in cortex per field of view (FOV) in terminally sick Pdgfbwt/wt, Pdgfbwt/ret, Pdgfbret/ret mice showed similar extent of
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vacuolation (inoculation route—intravenous, dose—3 log LD50) (one-way ANOVA, Tukey’s multiple comparison test,
p = 0.51 (B), p = 0.55 (C). Shown are means ±SD of biological replicates (N = 3–6). Scale bar: 10 μm.
https://doi.org/10.1371/journal.ppat.1007424.g002
Fig 3. PrPSc deposition after RML6 inoculation in control and BBB-compromised mice. Brain sections (cerebral cortex) were
stained for SAF84 to detect PrPSc deposits (dark brown) and co-stained with hematoxylin. Regardless of the inoculation route of
RML6 prions, all animals (Pdgfbwt/wt, Pdgfbwt/ret, Pdgfbret/ret) showed a similar extent of PrPSc deposition in their brains. No PrPSc
deposits were detected in mice that received NBH (normal brain homogenate). i.c.–intracerebral, i.p.–intraperitoneal, i.v.–
intravenous. Scale bar: 50 μm.
https://doi.org/10.1371/journal.ppat.1007424.g003
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When prions are administered peripherally, neuroinvasion is dependent on peripheral rep-
lication in lymphoid tissues [4]. Therefore we assessed the course of prion disease in Pdgfbret/ret
and control mice (Pdgfbwt/wt, Pdgfbwt/ret) after intraperitoneal administration of prions.
Similarly to intracerebral inoculation, Pdgfbret/ret and control mice (Pdgfbwt/wt, Pdgfbwt/ret)
showed no differences in prion disease pathogenesis after intraperitoneal inoculation (Fig 1B).
Thus, we conclude that the altered BBB does not affect prion neuroinvasion when prions are
administered peripherally nor lead to accelerated prion pathogenesis when administered
intracerebrally.
It has been previously claimed that intravenously injected prions reach the CNS within
minutes [7], and the authors of that study concluded that the quantity of PrPSc that reaches the
brain via the BBB is sufficient to induce the disease in mice possessing a normal BBB. How-
ever, another study with Syrian hamsters found that although prions were found in the CNS
few days after peripheral administration, the levels of prions were sub-infectious [21]. The
mode of PrPSc transport into the CNS via brain endothelium is not known. The brain vascula-
ture of Pdgfbret/ret mice is permeable to plasma proteins such as albumin, IgG, and the BBB per-
meability occurs at the level of endothelial transcytosis [10]. Normal brain endothelial cells
show a paucity of transcytotic vesicles, however, the increased transcytosis is seen as a first sign
of BBB defect in several brain insults (e.g. ischemic stroke) [22]. To directly assess the role of
the open BBB in prion pathogenesis, Pdgfbret/ret and control mice (Pdgfbwt/wt, Pdgfbwt/ret)
received RML6 intravenously, either a high dose (6 log LD50) or a low dose (3 log LD50). We
reasoned that Pdgfbret/ret animals should show an earlier onset of prion disease compared to
the control mice (Pdgfbwt/wt, Pdgfbwt/ret) since their BBB is permeable to plasma proteins. How-
ever, this was not the case, Pdgfbret/ret and control mice (Pdgfbwt/wt, Pdgfbwt/ret) animals did not
show any statistically significant differences in the speed of prion pathogenesis and in their
attack rate, either at high dose (6 log LD50, p = 0.37) or at low dose (3 log LD50, p = 0.86)
of intravenously administered prions (Fig 1C and 1D). The minimal trend towards earlier
lethality of Pdgfbret/ret mice was well within the biological variability expected in this kind of
experiments.
Our results using a mouse model with a compromised BBB due to increased transcytosis
show that the permeability of CNS vasculature has a negligible effect on prion disease trans-
mission into the CNS. This observation is in agreement with two decades of studies on the role
of lymphoid organs in prion spread. If prions could enter the brain directly after peripheral
inoculation, it would be difficult to understand why mice lacking B-cells [23] or complement
components [24] experienced delayed neuroinvasion, and why the distance between follicular
dendritic cells and peripheral nerve endings controls the speed of neuroinvasion [6]. Instead,
the current results validate a model by which peripherally administered prions first colonize
the lymphoid organs, then undergo a phase of clinically silent peripheral replication, and
finally achieve neuroinvasion by exploiting peripheral nerves belonging to the sympathetic
nervous system [5]. Therefore, prions resemble neurotropic viruses such as rhabdoviruses and
herpesviruses that utilize retrograde axonal transport to gain access to the central nervous sys-
tem, thereby bypassing the need for breaching the BBB. However, the limitation of our study
is that the amount of PrPSc in the brain parenchyma shorty after intravenous injection with
RML6 homogenate has not been quantified since currently available methods for detecting
infectious prions in the brain parenchyma shortly after inoculations are not sufficient for this
task.
Although Pdgfbret/ret and control mice (Pdgfbwt/wt, Pdgfbwt/ret) did not show differences in
the prion disease incubation, they may conceivably differ with respect to the histological and
biochemical hallmarks of prion infection. We therefore assessed the extent of spongiosis, the
most characteristic feature of TSEs, on hematoxylin-eosin stained brain sections. All prion-
The role of the blood-brain barrier in prion pathogenesis
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007424 November 29, 2018 9 / 15
inoculated animals, but none of the mice injected with NBH, showed the presence of spongio-
sis regardless of their genotype (Fig 2A). Quantification of vacuolation showed no difference
in number of vacuoles and area covered by vacuoles between Pdgfbret/ret and control mice
(Pdgfbwt/wt, Pdgfbwt/ret) (Fig 2B and 2C).
Microglia, whose activation in prion disease is considered neuroprotective partly by prion
clearance [25, 26], express Pdgfb [27]. Although it is unlikely that the lack of Pdgfb retention
motif will have a cell-autonomous effect on microglia—since microglia do not express the
receptor of Pdgfb—Pdgfrb, we nevertheless assessed microgliosis in terminal stage of the dis-
ease. No differences in number of microglia in between Pdgfbret/ret and control mice (Pdgfbwt/wt,
Pdgfbwt/ret) was detected (S3 Fig).
Finally, we investigated the levels of PrPSc accumulation using immunohistochemistry on
formalin-fixed paraffin-embedded tissue sections, Western blotting and fluorescence-resonance
energy transfer (FRET). Immunohistochemical analysis showed the presence of partially prote-
ase-resistant PrP (PrPSc) in the brains of all prion-inoculated mice, regardless of the genotype
and of the inoculation route, whereas NBH-injected mice never exhibited any PrPSc deposits
(Fig 3). Interestingly, Pdgfbret/ret mice showed more prominent accumulation of PrPSc along
blood vessels than wild-type mice (S4 Fig). All prion-inoculated animals showed PrPSc accumu-
lation in spleen (S5 Fig). Western blotting of partially proteinase K-resistant PrPSc showed simi-
lar levels of disease-associated PrP among the three genotypes (Pdgfbwt/wt, Pdgfbwt/ret, Pdgfbret/ret)
for all inoculation routes and prion doses (Fig 4A–4D). Quantification of PrPSc levels using a
FRET assay after PK digestion [18] did not show a difference in PrPSc levels between Pdgfbret/ret
and control mice (Pdgfbwt/wt, Pdgfbwt/ret) (Fig 4E). It is conceivable that BBB opening would
result in unorthodox prion replication and possibly in a strain shift [28]. Thus, we investigated
whether differences in the BBB permeability in Pdgfbret/ret mice lead to alteration in prion
strain. As a proxy for strain identification we quantified the ratio of the mono-, di-, and unglyco-
sylated forms of PrPSc. No significant difference between glycoform ratios were found among
genotypes (Fig 4F and 4G), suggesting that no shift in prion strains had taken place in Pdgfbret/ret
animals.
The altered BBB in Pdgfbret/ret mice in chronic inflammatory condition could lead to infiltra-
tion of peripheral leukocytes which could modify disease cause. However, other studies have
shown that during prion disease there is a minimal recruitment of inflammatory monocytes
and mice showing various T cell deficiencies develop clinical signs of prion disease with a com-
parable temporal dynamic/pattern to that seen in wild-type mice [23, 29]. The development
of prion disease does not differ between Pdgfbret/ret and control mice (Pdgfbwt/wt, Pdgfbwt/ret)
despite of the breached BBB of Pdgfbret/ret animals after all tested inoculation routes, including
intracerebral inoculation. Thus, if there is a component in pathology caused by peripheral leu-
kocytes then the effect on the disease has no detectable influence.
In conclusion, these data indicate that when prions are inoculated directly into the blood,
the intactness of the BBB has a negligible effect on the incubation time of the disease. This sug-
gests that extracerebrally administered prions do not need to trespass the BBB in order to
enter the CNS. Alternatively, one could construe that prions can trespass the neurovascular
barriers and colonize the brain through a mechanism that is fundamentally independent of the
BBB. There is no factual evidence supporting the latter scenario.
A wealth of data accrued in multiple model systems supports the idea that prions, after
entering the body from extraneural sites, undergo an early phase of replication in lymphoid
organs, which is then followed by the colonization of peripheral nerve endings. It is then
through the latter, according to this hypothesis, that prions eventually gain access to the CNS
—akin to neurotropic viruses such as rhabdo- and herpesviruses. If prion spread to the CNS
were directly hematogenic, one might expect the first site of CNS replication to be solely
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determined by the differential prion replication competence of select brain areas, rather than
by the site of inoculation. In reality, however, the first site of CNS invasion after intraperitoneal
inoculation with prions corresponds to the segmental projections of the peripheral nerves to
the spinal cord [5, 6]. Moreover, chemical or immunological sympathectomy suffices to pre-
vent neuroinvasion after intraperitoneal prion inoculation [5]. In the framework of the studies
Fig 4. Western blotting and FRET analysis of brain homogenates from terminally sick Pdgfbwt/wt, Pdgfbwt/ret, Pdgfbret/ret animals inoculated with RLM6. PrPC
(control) is fully digested by proteinase K whereas PrPSc results in the exposure of 27–30 kDa protease-resistant fragments. + or - PK: with or without proteinase K
digest. Intracerebrally (A), intraperitoneally (B), intravenously (C: 6 log LD50; D: 3 log LD50) inoculated control (Pdgfbwt/wt, Pdgfbwt/ret) and BBB-compromised
(Pdgfbret/ret) animals. Normal brain homogenate (NBH) inoculated animals were used as controls (Control). ���—di-glycosylated, ��—mono-glycosylated and �—
unglycosylated from of proteinase K-resistant PrPSc. (E) Quantification of PrPSc in brain homogenates in animals inoculated intravenously with RML 6 (3 log LD50)
using homogenous-FRET assay. The amount of proteinase K-resistant PrPSc in individual animals is expressed as a relative PrPSc amount compared to average of the
wild-type mice (Pdgfbwt/wt). No difference in PrPSc amount is seen in terminally sick Pdgfbwt/wt, Pdgfbwt/ret, Pdgfbret/ret animals (one-way ANOVA, Tukey’s multiple
comparison test, p = 0.15). Shown are means ±SD of biological replicates (N = 3–6). (F) The amount of PrPSc isoforms (expressed as percentage of total PrPSc) did not
differ between control (Pdgfbwt/wt, Pdgfbwt/ret) and Pdgfbret/ret animals (inoculation route—intravenous, dose—3 log LD50) (Two-way ANOVA, Bonferroni correction,
p>0.05). Shown are mean ± SD of biological replicates (N = 3–6). (G) Tri-blot of glycoform percentages (see F) of PrPSc isoforms. Shown are biological replicates.
Pdgfbwt/wt are in blue, Pdgfbwt/ret are in red and Pdgfbret/ret are in black. Tri-blot was generated in Excel using a template (Tri-blot v1.4.2) published by Graham and
Midgley [30].
https://doi.org/10.1371/journal.ppat.1007424.g004
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enumerated above, the data reported here add to the conjecture that prion spread from the
periphery to the brain does not occur by direct transition across the BBB. Besides their signifi-
cance for the basic understanding of prion neuroinvasion, these results may be of relevance to
the possibility of developing effective post-exposure prophylaxis of prion diseases, which may
prevent neurodegeneration even after extraneural infection has already taken place.
Supporting information
S1 Fig. Single horizontal image plane extracted from SPIM images of Pdgfbwt/ret (A) and
Pdgfbret/ret (B) animals demonstrating the entry of the 70 kDa-dextran Texas Red into
the brain parenchyma in Pdgfbret/ret animals. The dynamic range of the Pdgfbwt/ret image (A)
was adjusted to show the background fluorescence emphasizing the lack of tracer in the brain.
Excitation laser wavelength 594 nm, emission filtered with a 594 nm long pass filter. Optical
slice thickness: 25 μm. Scale bar: 1 mm.
(PDF)
S2 Fig. Prion histopathology after RML6 inoculation in control and BBB-compromised
mice. Hematoxylin/eosin stained sections from the cerebella of prion-inoculated terminally
sick (or control, NBH inoculated mice) Pdgfbwt/wt, Pdgfbwt/ret, Pdgfbret/ret animals showed simi-
lar extent of vacuolation. Scale bar: 100 μm.
(PDF)
S3 Fig. The BBB-defect in Pdgfbret/ret animals did not alter microglia activation and num-
ber in terminally sick animals (inoculation route—Intravenous, dose—3 log LD50). A.
Brain sections were stained for Iba1 to detect microglia in cortex and costained with hematox-
ylin. Scale bar: 100 μm. B. Quantification of Iba 1 positive cells in the cortex did not show a
difference in microglia numbers between all tested genotypes (one-way ANOVA, Tukey’s mul-
tiple comparison test, p = 0.17) Shown are mean ±SD of biological replicates (N = 3–4).
(PDF)
S4 Fig. PrPSc deposition after RML6 inoculation in control and BBB-compromised mice.
Brain sections (corpus callosum) were stained for SAF84 to detect PrPSc deposits (dark brown)
and co-stained with hematoxylin. Mice were intravenously inoculated (6 log LD50) with
RML6. Pdgfbret/ret mice show conspicuous PrPSc deposits (arrows, B”) along the vasculature
(arrow, A”). Such deposits were not visible in Pdgfbwt/wt mice. Scale bars: 100 μm (A, B), 50 μm
(A’, B’), 10 μm (A”, B”).
(PDF)
S5 Fig. Splenic PrPSc deposition after RML6 inoculation in control and BBB-compromised
mice. Spleen sections were stained for SAF84 to detect PrPSc deposits (dark brown) and co-
stained with hematoxylin. Regardless of the inoculation route of RML6, all animals (Pdgfbwt/wt,
Pdgfbwt/ret, Pdgfbret/ret) showed PrPSc deposits in the spleen. No PrPSc deposits were detected in
mice that received normal brain homogenate (NBH). Scale bar: 50 m.
(PDF)
S1 Movie. Video based on SPIM recordings (594 nm excitation, 594 nm long pass filter) of
Pdgfbret/ret mouse brain showing extravasated 70 kDa dextran-Texas Red. Start– 6 sec: pre-
senting the 3D reconstruction of whole brain showing background fluorescence (594 nm exci-
tation, 594 nm long pass filter); 7 sec– 16 sec: presenting z-stacks of optical sections showing
dextran-Texas Red signal in red; 17 sec—end: a combined 3D reconstruction of whole brain
(background autofluorescence combined with the signal from extravasated dextran Texas
Red) demonstrates compromised BBB in the entire brain of Pdgfbret/ret mice. The most
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prominent BBB breakdown is seen in cerebral cortex.
(MP4)
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